Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now

Senseonics Holdings, Inc.

1 day chart

Created with Highcharts 11.1.0
Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About SENS

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.

Find out what a historical investment in Senseonics Holdings, Inc. would be worth today using our SENS stock calculator.

Market Capitalisation

$408.93M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

8.92M

High today

$0.73

Low today

$0.62

Open price

$0.70

52-week high

$1.40

52-week low

$0.25

Ready to start your investing journey with Stake?

Open an account

What does Senseonics do and how does it earn money?

It's in the blood. Senseonics Holdings, Inc. is a medical technology company that develops and manufactures Continuous Glucose Monitoring (CGM) systems, aiming “to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy.” 

The company’s CGMs are an industry first. While others require weekly or fortnightly replacements, Senseonics’ CGMs can be implanted subcutaneously for much longer periods.

The company earns revenue in one business segment via three main products: 

  • Eversense CGM which can be implanted subcutaneously for 3 months 

  • Eversense XL CGM which can be implanted subcutaneously for 6 months (currently available in Europe only)

  • Eversense E3 CGM which can be implanted subcutaneously for 6 months

In August 2020, Senseonics entered a Commercialization Agreement with Ascensia, a global diabetes treatment company. Senseonics granted Ascensia exclusive rights to distribute their Eversense CGM systems worldwide.

How does Senseonics’ Eversense CGM work?

Senseonics’ CGM systems measure a diabetic’s glucose levels (aka blood sugar) via sensors inserted under the skin by a healthcare professional. 

The sensor communicates data to a smart transmitter on top of the skin. The transmitter beams data to a smartphone app for real-time diabetes monitoring and management.

Is Senseonics profitable?

No, Senseonics is not profitable at this time. 

By their own admission, the company is in “the early commercialization stages of the Eversense brand and are focused on driving awareness of our CGM systems amongst intensively managed patients and their healthcare providers.”

Revenue has see-sawed since the company went public and net income has always been negative. In fact, net income has trended deeper into the red in FY2019, FY2020 and FY2021 with minus US$116m, US$175m and US$302m, respectively.

As of the end of FY2021, the company has accumulated a total debt of US$62.7m.

Is SENS stock a buy?

Investor sentiment on SENS is mixed. Some investors consider Senseonics uninvestable due to its weak and inconsistent financials. 

Other investors anticipate a brighter future for the company due to the U.S. Food & Drug Administration’s (FDA) recent approval of the Eversense E3 CGM system in February 2022.

These investors are also anticipating widening adoption of Eversense CGMs due to the Commercialization Agreement with Ascensia.

Who owns SENS stock?

Senseonics largest shareholders are institutional including PHC Holdings Corporation (14.75%), BlackRock (6.71%), Vanguard Group (4.35%) and Steward Capital Holdings (4.1%).

President and CEO Timothy T. Goodnow holds 0.3%.


SENS FAQs

Buying SENS shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Senseonics Holdings, Inc. in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in SENS

The ticker symbol for Senseonics Holdings, Inc. is SENS.

One share of SENS is valued at $0.63 as of 12 May 2025.

As of 12 May 2025 Senseonics Holdings, Inc. has a market cap of $408.93M.

The Senseonics Holdings, Inc. 52-week high stock price is $1.40.

The Senseonics Holdings, Inc. 52-week low stock price is $0.25.

Yes, the Stake investing platform allows you to buy SENS shares and over 12,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in SENS
on Stake

Buy SENS from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of SENS from only US$10 with fractional shares

Get started
Stake app chart
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
SENS related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2025 Stake. All rights reserved.

This site uses cookies. By using our site you agree to the Stake Privacy Policy.